Related Experiment Video
Updated: Aug 15, 2026
![Solid-phase Synthesis of [4.4] Spirocyclic Oximes](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58508.jpg&w=3840&q=50)
05:15
Solid-phase Synthesis of [4.4] Spirocyclic Oximes
Published on: February 6, 2019
OSI-461 (OSI)
1INSERM 590, University Claude Bernard Lyon 1, 8 Avenue Rockefeller, 69373 Lyon, France. fgalma@rockefeller.univ-lyon1.fr
Current Opinion in Investigational Drugs (London, England : 2000)
|July 10, 2004
Abstract:
OSI Pharmaceuticals is developing OSI-461, a potent analog of exisulind, for the potential treatment of cancer and inflammatory bowel disease. In August 2001, OSI-461 entered phase II trials involving patients with chronic lymphocytic leukemia. In July 2002, the company embarked on a pilot phase II study evaluating OSI-461 for the treatment of Crohn's disease. By October 2002, Cell Pathways had selected hormone-refractory prostate cancer as the lead cancer indication for clinical development of OSI-461.
